What is Elucidata?
Founded in 2015 and based in Cambridge, MA, Elucidata operates within the biomedical data analysis industry. The company's core offering is its platform, Polly, which provides comprehensive data analysis services. These services encompass critical functions such as data storage, secure data transfer and file access, and the analysis of screening data, among other advanced capabilities. Elucidata aims to streamline and enhance the complex process of biomedical data management and interpretation for researchers and organizations.
How much funding has Elucidata raised?
Elucidata has raised a total of $21M across 2 funding rounds:
Other Financing Round
$5M
Series A
$16M
Other Financing Round (2021): $5M with participation from Hyperplane Venture Capital and IvyCap Ventures
Series A (2022): $16M led by F-Prime Capital Partners, Hyperplane Venture Capital, IvyCap Ventures, and Eight Roads
Key Investors in Elucidata
F-Prime Capital Partners
F-Prime Capital Partners, established in 2002, is an investment firm focused on healthcare and technology sectors, bringing a multidisciplinary team of investors, engineers, doctors, and scientists to support portfolio companies.
Hyperplane Venture Capital
Hyperplane Venture Capital is a seed-stage investment firm based in Boston, Massachusetts, specializing in companies leveraging machine intelligence, sensor technology, and cloud computing across various industries including digital health.
IvyCap Ventures
IvyCap Ventures, founded in 2011, is a venture capital firm that supports entrepreneurs from leading Indian educational institutions, investing in early to growth-stage startups across sectors like DeepTech, HealthTech, and SaaS.
What's next for Elucidata?
The recent major strategic investment signals a pivotal phase for Elucidata, likely indicating a move towards scaling operations and broadening its market reach. This capital infusion, part of its $21M in total financing, suggests strong investor confidence in Elucidata's technology and business model. The company is poised to leverage this backing to enhance its Polly platform, potentially expanding its service offerings, forging new strategic partnerships, and accelerating its growth within the rapidly evolving field of biomedical informatics. Future developments may include further platform enhancements and increased market penetration.
See full Elucidata company page
